双联抗血小板治疗对下肢旁路移植术后移植物通畅性的影响
本研究基于美国血管质量倡议(VQI)数据库2003至2018年13020例下肢旁路移植术患者,回顾分析出院时阿司匹林单药与双联抗血小板治疗(DAPT)的处方趋势及对移植物通畅性的影响。结果显示DAPT使用比例从10.6%升至60.6%,但校正混杂因素后DAPT对总体通畅性无显著获益,仅在人工血管旁路亚组中与更优通畅性相关。
要点
- 下肢旁路移植术后DAPT处方比例从2003年10.6%显著增至2018年60.6%(P < .001)。
- 总体校正分析中DAPT与阿司匹林单药在初级、初级辅助及次级通畅性上均无显著差异。
- 人工血管旁路亚组中DAPT与更优通畅性相关,但需进一步研究最佳疗程及出血风险。
核心结论
- 下肢旁路移植术后DAPT使用比例显著增加,但校正混杂因素后对总体移植物通畅性无获益。
- 亚组分析中DAPT仅在接受人工血管旁路的患者中与改善的通畅性相关。
研究设计与样本
- 回顾性分析前瞻性收集的美国血管质量倡议(VQI)数据库2003至2018年非急诊腹股沟下下肢旁路移植术患者,共13020例。
- 比较出院时阿司匹林单药(52.2%)与DAPT(47.8%)两组,采用线性回归分析处方趋势,多变量Cox回归分析通畅性预测因素。
主要发现
- DAPT组患者更年轻,合并高血压、糖尿病、充血性心力衰竭、慢性阻塞性肺疾病及动脉粥样硬化疾病比例更高,且旁路手术风险更高(更远端靶血管、既往流入道旁路、人工血管使用)。
- 多变量Cox回归显示DAPT与阿司匹林单药在初级通畅性(HR 0.98;95%CI 0.88-1.10;P = .78)、初级辅助通畅性(HR 0.93;95%CI 0.80-1.07;P = .30)及次级通畅性(HR 0.88;95%CI 0.74-1.06;P = .18)上均无显著差异。
- 人工血管旁路亚组中DAPT与更优通畅性相关:初级通畅性HR 0.81(95%CI 0.66-1.00;P = .05),初级辅助通畅性HR 0.74(95%CI 0.58-0.94;P = .01),次级通畅性HR 0.60(95%CI 0.44-0.82;P < .001)。
- 其他旁路导管类型的校正亚组分析未观察到通畅性差异。
关键数值与推荐
- DAPT出院比例从2003年10.6%上升至2018年60.6%(P < .001)。
- 总体队列中DAPT与阿司匹林单药相比,初级通畅性HR 0.98(95%CI 0.88-1.10;P = .78)。
- 人工血管旁路亚组中DAPT的次级通畅性HR 0.60(95%CI 0.44-0.82;P < .001)。
临床怎么用
- 下肢旁路移植术后DAPT使用普遍增加,但总体人群中选择DAPT需权衡患者合并症与手术风险特征。
- 对于接受人工血管旁路的患者,DAPT可能改善移植物通畅性,可考虑个体化应用。
- DAPT的最佳疗程及出血并发症风险仍需进一步研究明确。
局限性
- 本研究为回顾性分析,存在选择偏倚和未测量混杂因素的可能。
- 原文未报告DAPT具体药物组合、剂量及治疗持续时间。
- 原文未报告出血并发症及主要不良肢体事件的具体数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current guidelines recommend single-agent antiplatelet therapy for patients with symptomatic peripheral artery disease and consideration of dual antiplatelet therapy (DAPT) after surgical revascularization. The objective of this study was both to explore prescribing patterns of single antiplatelet therapy vs DAPT after lower extremity bypass surgery and to investigate the effects of antiplatelet therapy on bypass graft patency. METHODS: A retrospective analysis of prospectively collected nonemergent infrainguinal lower extremity bypass operations entered in the national Vascular Quality Initiative (2003-2018) with captured long-term follow-up was performed. Patients discharged on aspirin monotherapy or DAPT were identified. Linear regression investigated temporal trends in antiplatelet use. Multivariable Cox regression investigated predictors of primary, primary assisted, and secondary patency. RESULTS: Of the 13,020 patients investigated, 52.2% were discharged on aspirin monotherapy and 47.8% on DAPT. The proportion of patients discharged on DAPT increased from 10.6% in 2003 to 60.6% in 2018 (P < .001). The DAPT cohort was younger, had higher rates of medical (hypertension, diabetes, congestive heart failure, chronic obstructive pulmonary disease) and atherosclerotic (coronary artery disease, prior coronary artery bypass graft or percutaneous coronary intervention, prior lower extremity intervention) comorbidities, and had higher risk bypass procedures (more distal targets, prior inflow bypass procedure, prosthetic conduit use). Multivariable Cox regression analysis did not show any difference between the DAPT and aspirin cohorts in primary patency (hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.88-1.10; P = .78), primary assisted patency (HR, 0.93; 95% CI, 0.80-1.07; P = .30), or secondary patency (HR, 0.88; 95% CI, 0.74-1.06; P = .18). On subgroup analysis based on bypass conduit, DAPT was found to have a protective effect on patency only in the prosthetic bypass cohort (primary patency: HR, 0.81 [95% CI, 0.66-1.00; P = .05]; primary assisted patency: HR, 0.74 [95% CI, 0.58-0.94; P = .01]; and secondary patency: HR, 0.60 [95% CI, 0.44-0.82; P < .001]). No patency differences were observed on adjusted subgroup analysis for the other bypass conduits. CONCLUSIONS: A significant and increasing proportion of patients are discharged on DAPT after lower extremity bypass revascularization. These patients represent a higher risk cohort with more medical comorbidities and higher risk bypass features. After controlling for these differences, DAPT therapy had no beneficial effect on overall bypass graft patency or major adverse limb events. However, on subgroup analysis, DAPT was associated with improved bypass graft patency in patients receiving prosthetic bypass conduits. Further study is warranted to investigate optimal duration of DAPT therapy and its possible bleeding complications in prosthetic bypass patients.
引用
- Belkin N, Stoecker JB, Jackson BM, et al. Effects of dual antiplatelet therapy on graft patency after lower extremity bypass. J Vasc Surg. 2020. PMID: 32777321. doi:10.1016/j.jvs.2020.06.127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。